MindWalk vs ProQR Therapeutics
HYFT and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HYFT and PRQR compare
MindWalk grew revenue faster over the last twelve months (43.4% versus 11.4% for ProQR Therapeutics).
MindWalk scores higher on the StockData Score (7 against 6 for ProQR Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HYFT | PRQR |
|---|---|---|
| Size and price | ||
| Share price | $0.990 | $1.41 |
| Change, 1 year | −44.7% | −34.7% |
| Change, 5 years | −82.1% | −81.9% |
| Beta (5Y) | 1.36 | 1.26 |
| Employees | – | 59 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 43.4% (better) | 11.4% |
| Revenue growth, 5Y average | −2.8% | – |
| Profitability | ||
| Gross margin | 60.8% | – |
| Operating margin | – | −233% |
| Net margin | – | −229% |
| FCF margin | −76.9% (better) | −273% |
| Return on equity | – | −57.4% |
| Financial health | ||
| Debt / equity | – | 0.06 |
| Current ratio | 1.84 | 3.49 (better) |
| Piotroski F-score | – | 1 |
| Ownership | ||
| Held by institutions | 9.3% | 57.6% |
| Held by insiders | 0.00% | 37.8% |
| Insider net buying, 12 months | – | $1.3M |
Go deeper
- HYFT stock overview
- HYFT income statement
- HYFT valuation and score
- PRQR stock overview
- PRQR income statement
- PRQR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.